Hub : Traits :

Worrier / anxious feelings

744 significantly associated models · 126 unique genes.

Significant Loci

# chr p0 p1 # assoc genes # joint genes best TWAS P best SNP P cond SNP P % var exp joint genes
1 3 49598064 51234774 7 2 1.8e-10 5.2e-08 0.582 99 CYB561D2 SEMA3B-AS1
2 3 51616334 54077726 13 1 1.2e-13 1.3e-11 0.115 95 ITIH4-AS1
3 3 84317575 86808226 1 1 2.4e-16 3.6e-16 1.000 100 CADM2
4 3 135173458 137261517 5 1 2.0e-11 1.6e-10 1.000 100 STAG1
5 4 118707160 119423789 1 1 2.1e-07 6.9e-07 0.030 81 NDST3
6 5 101762909 103244640 1 1 1.5e-07 2.1e-08 0.050 88 PPIP5K2
7 7 126529931 128425768 3 2 4.8e-09 2.3e-10 0.011 84 LRRC4 SND1
8 8 8092025 13120332 40 1 5.9e-28 4.2e-24 0.323 99 AF131215.2
9 10 103527782 105647095 12 1 2.5e-13 1.1e-11 0.806 100 AS3MT
10 11 56666189 58178587 4 1 7.7e-09 5.8e-08 0.891 100 ZDHHC5
11 11 94825532 96261289 2 1 1.6e-08 6.3e-08 0.217 95 AP001877.1
12 11 130498156 131034037 1 1 1.5e-07 3.7e-06 0.736 100 SNX19
13 11 133079948 134525648 1 1 9.2e-09 3.0e-08 0.079 90 IGSF9B
14 12 109231851 110605559 1 1 8.1e-08 1.7e-07 0.205 94 KCTD10
15 14 74424938 76210831 5 2 2.7e-11 3.0e-10 0.999 100 AREL1 MLH3
16 16 29580611 31758245 7 2 3.9e-08 4.2e-08 0.601 99 MYST1 YPEL3
17 17 42607368 45796313 18 1 5.4e-09 3.1e-08 0.863 100 MAPT
18 18 52209411 54028036 1 1 1.5e-09 2.3e-10 0.017 86 TCF4
19 22 40472399 41895409 1 1 1.1e-07 8.1e-08 0.199 94 SLC25A17

Pleiotropic Associations

Trait chisq ratio # genes+ # genes++ % genes++ corr corr P genes
Bipolar Disorder or Schizophrenia 4.64 5 4 8.9 1.00 1.8e-04 AS3MT IGSF9B ITIH4-AS1 NDST3 SLC25A17
Depressed Affect (Nagel 2018) 6.50 8 2 4.4 0.95 2.5e-04 AREL1 KCTD10 MAPT MLH3 MYST1 STAG1 TCF4 ZDHHC5
Depression (Nagel 2018) 5.67 4 2 4.4 1.00 6.9e-04 CYB561D2 MAPT STAG1 ZDHHC5
Intelligence (Savage-Jansen 2018) 4.32 8 4 8.9 -0.98 2.7e-05 AP001877.1 ITIH4-AS1 LRRC4 MAPT PPIP5K2 SND1 STAG1 ZDHHC5
Neuroticism (Nagel 2018) 12.69 15 12 26.7 0.95 3.5e-08 AREL1 AS3MT CYB561D2 IGSF9B ITIH4-AS1 KCTD10 MAPT MLH3 MYST1 NDST3 SLC25A17 SNX19 STAG1 TCF4 ZDHHC5
Schizophrenia (2018) 5.39 6 3 6.7 0.98 7.0e-04 AS3MT IGSF9B ITIH4-AS1 SLC25A17 STAG1 ZDHHC5
Worry (Nagel 2018) 15.87 19 14 31.1 0.99 2.5e-15 AP001877.1 AREL1 AS3MT CADM2 CYB561D2 IGSF9B ITIH4-AS1 KCTD10 MAPT MLH3 MYST1 NDST3 PPIP5K2 SEMA3B-AS1 SLC25A17 SNX19 STAG1 YPEL3 ZDHHC5
Alzheimer’s Disease (including proxy) 2.22 2 0 0.0 0.00 1.0e+00 MYST1 YPEL3
Major Depression (MDD) 4.10 2 0 0.0 0.00 1.0e+00 TCF4 ZDHHC5
Verbal and Numeric Reasoning (VNR) 4.23 4 2 4.4 -0.99 1.2e-02 ITIH4-AS1 MAPT PPIP5K2 SND1
Breast Cancer 1.65 1 1 2.2 0.00 1.0e+00 MAPT
Ovarian Cancer 2.27 1 1 2.2 0.00 1.0e+00 MAPT
Coronary Artery Disease (CAD) 2.27 1 0 0.0 0.00 1.0e+00 AS3MT
HDL Cholesterol 1.74 1 1 2.2 0.00 1.0e+00 KCTD10
Lupus 1.63 1 0 0.0 0.00 1.0e+00 AF131215.2
Neuroticism (2016) 8.39 5 2 4.4 0.99 1.1e-03 AF131215.2 AREL1 MAPT SLC25A17 TCF4
Rheumatoid Arthritis 1.94 1 0 0.0 0.00 1.0e+00 PPIP5K2
Schizophrenia (2014) 5.87 7 3 6.7 0.98 1.3e-04 AS3MT IGSF9B ITIH4-AS1 SLC25A17 SNX19 STAG1 ZDHHC5
Triglycerides 1.52 1 0 0.0 0.00 1.0e+00 MYST1
Blood Eosinophil Count 2.23 5 5 11.1 0.22 7.2e-01 ITIH4-AS1 KCTD10 MAPT SLC25A17 YPEL3
Blood Platelet Count 1.32 8 5 11.1 -0.45 2.7e-01 AREL1 AS3MT CYB561D2 ITIH4-AS1 SND1 STAG1 YPEL3 ZDHHC5
Blood Red Count 3.40 9 5 11.1 0.70 3.6e-02 AP001877.1 AS3MT CYB561D2 ITIH4-AS1 MAPT MYST1 PPIP5K2 YPEL3 ZDHHC5
Blood White Count 0.81 3 1 2.2 0.00 1.0e+00 KCTD10 MAPT PPIP5K2
Heel T-Score 1.72 6 1 2.2 0.28 5.8e-01 AREL1 MAPT MLH3 MYST1 SLC25A17 ZDHHC5
BMI 3.14 6 6 13.3 -0.99 1.4e-04 AS3MT CADM2 ITIH4-AS1 MYST1 SNX19 YPEL3
Height 1.86 12 9 20.0 -0.06 8.6e-01 AP001877.1 AREL1 AS3MT CYB561D2 ITIH4-AS1 MAPT NDST3 PPIP5K2 SEMA3B-AS1 STAG1 TCF4 YPEL3
Waist Hip Ratio (WHR) 2.97 5 5 11.1 0.65 2.3e-01 CYB561D2 ITIH4-AS1 MAPT PPIP5K2 STAG1
Systolic Blood Pressure 3.67 7 6 13.3 0.25 5.8e-01 AREL1 AS3MT CADM2 MAPT SND1 YPEL3 ZDHHC5
Smoking Status 4.77 3 2 4.4 0.00 1.0e+00 AS3MT CADM2 ITIH4-AS1
Allergy or Eczema 1.22 1 1 2.2 0.00 1.0e+00 SLC25A17
Cardiovascular Disease 1.92 2 1 2.2 0.00 1.0e+00 AS3MT MYST1
Hypothyroidism (self reported) 1.97 1 1 2.2 0.00 1.0e+00 PPIP5K2
Type 2 Diabetes (T2D) (2018) 2.03 1 0 0.0 0.00 1.0e+00 PPIP5K2
Lung FEV1/FVC ratio 1.47 3 1 2.2 0.00 1.0e+00 AREL1 MAPT ZDHHC5
Lung FVC 3.54 4 4 8.9 -0.49 5.1e-01 MAPT MYST1 SEMA3B-AS1 TCF4
Neuroticism 12.07 15 11 24.4 0.95 5.7e-08 AREL1 AS3MT CADM2 CYB561D2 IGSF9B KCTD10 MAPT MLH3 MYST1 NDST3 SEMA3B-AS1 SLC25A17 STAG1 TCF4 ZDHHC5
Chronotype (morning person) 1.88 1 1 2.2 0.00 1.0e+00 CYB561D2
Hair Pigment 0.14 1 1 2.2 0.00 1.0e+00 SLC25A17
Tanning 0.79 3 1 2.2 0.00 1.0e+00 AREL1 CADM2 ITIH4-AS1
Hand grip strength (left) 5.50 9 4 8.9 -0.19 6.3e-01 AREL1 AS3MT CADM2 IGSF9B ITIH4-AS1 LRRC4 MAPT TCF4 YPEL3
Number of treatments/medications taken 3.20 1 1 2.2 0.00 1.0e+00 AREL1
Sensitivity / hurt feelings 8.71 7 2 4.4 0.84 1.7e-02 AF131215.2 IGSF9B KCTD10 MAPT NDST3 STAG1 ZDHHC5
Frequency of depressed mood in last 2 weeks 6.05 4 0 0.0 1.00 1.7e-03 CYB561D2 MAPT STAG1 ZDHHC5
Hearing difficulty/problems: Yes 1.82 1 0 0.0 0.00 1.0e+00 MAPT
Relative age of first facial hair 3.05 1 1 2.2 0.00 1.0e+00 MAPT
Systolic blood pressure, automated reading 3.82 5 3 6.7 -0.40 5.1e-01 AF131215.2 AREL1 AS3MT MAPT ZDHHC5
Impedance of leg (right) 4.77 12 9 20.0 0.77 3.3e-03 AF131215.2 AP001877.1 AREL1 AS3MT CADM2 CYB561D2 ITIH4-AS1 LRRC4 MAPT MLH3 SEMA3B-AS1 YPEL3
Leg fat-free mass (left) 2.86 5 4 8.9 -0.89 4.5e-02 AF131215.2 AS3MT CADM2 MYST1 YPEL3
Trunk fat percentage 3.04 6 4 8.9 -0.43 3.9e-01 AREL1 MAPT MYST1 SLC25A17 SNX19 ZDHHC5
Hand grip strength (right) 3.94 5 1 2.2 0.16 7.9e-01 CADM2 MAPT NDST3 TCF4 YPEL3
Current tobacco smoking 2.60 2 0 0.0 0.00 1.0e+00 AS3MT SLC25A17
Maternal smoking around birth 2.14 1 0 0.0 0.00 1.0e+00 AS3MT
Fed-up feelings 5.76 5 4 8.9 0.96 9.9e-03 AF131215.2 AREL1 MAPT STAG1 ZDHHC5
Frequency of unenthusiasm / disinterest in last 2 weeks 4.71 2 0 0.0 0.00 1.0e+00 STAG1 ZDHHC5
Relative age voice broke 2.32 1 1 2.2 0.00 1.0e+00 MAPT
Taking other prescription medications 3.31 1 1 2.2 0.00 1.0e+00 AREL1
Age when periods started (menarche) 1.37 1 0 0.0 0.00 1.0e+00 MAPT
Heel bone mineral density (BMD) T-score, automated (left) 3.17 2 1 2.2 0.00 1.0e+00 AF131215.2 MAPT
High blood pressure 2.52 3 1 2.2 0.00 1.0e+00 AF131215.2 MAPT MYST1
Sitting height 1.58 4 4 8.9 -0.46 5.4e-01 ITIH4-AS1 MAPT YPEL3 ZDHHC5
Body mass index (BMI) 3.73 7 7 15.6 -0.97 2.5e-04 AF131215.2 AS3MT CADM2 ITIH4-AS1 MYST1 SNX19 YPEL3
Impedance of leg (left) 4.61 12 9 20.0 0.77 3.3e-03 AF131215.2 AP001877.1 AREL1 AS3MT CADM2 CYB561D2 ITIH4-AS1 LRRC4 MAPT MLH3 SEMA3B-AS1 YPEL3
Leg predicted mass (left) 2.85 5 4 8.9 -0.89 4.6e-02 AF131215.2 AS3MT CADM2 MYST1 YPEL3
Trunk fat mass 2.90 6 4 8.9 -0.94 4.5e-03 AS3MT CADM2 MAPT MYST1 SNX19 YPEL3
Waist circumference 2.78 5 3 6.7 -0.96 9.0e-03 AS3MT CADM2 MYST1 SNX19 YPEL3
Number of incorrect matches in round 4.01 3 0 0.0 0.00 1.0e+00 AS3MT MYST1 NDST3
Past tobacco smoking 4.48 3 2 4.4 0.00 1.0e+00 AS3MT CADM2 ITIH4-AS1
Alcohol usually taken with meals 2.01 1 0 0.0 0.00 1.0e+00 ZDHHC5
Nervous feelings 13.03 13 9 20.0 0.99 1.1e-10 AF131215.2 AREL1 AS3MT CADM2 CYB561D2 ITIH4-AS1 MAPT MYST1 SEMA3B-AS1 SLC25A17 SNX19 STAG1 YPEL3
Frequency of tenseness / restlessness in last 2 weeks 6.02 3 2 4.4 0.00 1.0e+00 KCTD10 MAPT STAG1
Hearing difficulty/problems with background noise 2.38 1 1 2.2 0.00 1.0e+00 MAPT
Hair/balding pattern: Pattern 2 1.75 1 0 0.0 0.00 1.0e+00 MAPT
Had menopause 1.84 1 0 0.0 0.00 1.0e+00 SEMA3B-AS1
Forced vital capacity (FVC) 2.99 4 2 4.4 0.34 6.6e-01 ITIH4-AS1 MAPT MYST1 NDST3
Heel bone mineral density (BMD) T-score, automated (right) 3.21 2 1 2.2 0.00 1.0e+00 AF131215.2 MAPT
Ever unenthusiastic/disinterested for a whole week 3.30 1 0 0.0 0.00 1.0e+00 MAPT
Qualifications: None of the above 2.82 1 1 2.2 0.00 1.0e+00 AP001877.1
Mouth/teeth dental problems 2.23 2 0 0.0 0.00 1.0e+00 KCTD10 MAPT
Fluid intelligence score 3.22 3 0 0.0 0.00 1.0e+00 MAPT PPIP5K2 STAG1
Illnesses of siblings 1.70 1 0 0.0 0.00 1.0e+00 MYST1
Neuroticism score 13.59 15 9 20.0 0.98 3.6e-10 AF131215.2 AREL1 CYB561D2 IGSF9B KCTD10 MAPT MLH3 MYST1 NDST3 SEMA3B-AS1 SLC25A17 SNX19 STAG1 TCF4 ZDHHC5
Weight 3.08 6 6 13.3 -0.90 1.3e-02 AF131215.2 AS3MT CADM2 MYST1 SNX19 YPEL3
Impedance of arm (right) 4.53 9 5 11.1 0.72 2.8e-02 AF131215.2 CADM2 CYB561D2 ITIH4-AS1 MAPT MLH3 SEMA3B-AS1 YPEL3 ZDHHC5
Arm fat percentage (right) 3.18 7 4 8.9 -0.68 9.5e-02 AF131215.2 AS3MT ITIH4-AS1 MYST1 SNX19 YPEL3 ZDHHC5
Trunk fat-free mass 2.59 5 3 6.7 -0.81 9.9e-02 AF131215.2 AS3MT CADM2 MLH3 YPEL3
Hip circumference 3.22 6 4 8.9 -0.88 2.0e-02 AF131215.2 AS3MT CADM2 MYST1 SNX19 YPEL3
Frequency of tiredness / lethargy in last 2 weeks 4.09 3 1 2.2 0.00 1.0e+00 KCTD10 STAG1 ZDHHC5
Falls in the last year 2.85 1 1 2.2 0.00 1.0e+00 SEMA3B-AS1
Hair/balding pattern: Pattern 3 3.40 1 1 2.2 0.00 1.0e+00 MAPT
Number of live births 2.42 2 1 2.2 0.00 1.0e+00 CADM2 MAPT
Forced expiratory volume in 1-second (FEV1) 3.53 4 2 4.4 0.44 5.6e-01 AF131215.2 MAPT MYST1 NDST3
Noisy workplace 1.36 1 0 0.0 0.00 1.0e+00 MAPT
Qualifications: A levels/AS levels or equivalent 3.09 3 1 2.2 0.00 1.0e+00 AP001877.1 MAPT NDST3
Serious illness, injury or assault of a close relative in last 2 years 2.39 1 0 0.0 0.00 1.0e+00 SND1
Mouth/teeth dental problems: Dentures 2.36 2 0 0.0 0.00 1.0e+00 AF131215.2 STAG1
Medication: Ibuprofen (e.g. Nurofen) 1.54 1 0 0.0 0.00 1.0e+00 MAPT
Forced expiratory volume in 1-second (FEV1), Best measure 3.16 2 2 4.4 0.00 1.0e+00 MAPT MYST1
Impedance of arm (left) 4.47 9 5 11.1 0.72 2.9e-02 AF131215.2 AS3MT CADM2 CYB561D2 ITIH4-AS1 MAPT SEMA3B-AS1 YPEL3 ZDHHC5
Arm fat mass (right) 3.30 6 5 11.1 -0.93 7.1e-03 AF131215.2 AS3MT CADM2 MYST1 SNX19 YPEL3
Trunk predicted mass 2.60 5 3 6.7 -0.81 9.9e-02 AF131215.2 AS3MT CADM2 MLH3 YPEL3
Standing height 1.78 8 5 11.1 0.11 7.9e-01 AF131215.2 AS3MT ITIH4-AS1 MAPT PPIP5K2 SEMA3B-AS1 STAG1 YPEL3
Tense / 'highly strung' 8.41 9 2 4.4 0.98 4.7e-06 AF131215.2 AREL1 CADM2 CYB561D2 MAPT MYST1 SEMA3B-AS1 SLC25A17 STAG1
Seen doctor (GP) for nerves, anxiety, tension or depression 4.93 3 1 2.2 0.00 1.0e+00 AREL1 IGSF9B TCF4
Hair/balding pattern: Pattern 4 4.98 1 1 2.2 0.00 1.0e+00 MAPT
Birth weight of first child 2.22 2 0 0.0 0.00 1.0e+00 AS3MT SND1
Peak expiratory flow (PEF) 3.24 3 1 2.2 0.00 1.0e+00 AF131215.2 MAPT NDST3
Qualifications: O levels/GCSEs or equivalent 2.26 1 0 0.0 0.00 1.0e+00 AP001877.1
Medication: Paracetamol 4.22 1 1 2.2 0.00 1.0e+00 MAPT
Headache pain in last month 4.32 3 1 2.2 0.00 1.0e+00 ITIH4-AS1 MAPT ZDHHC5
Hypothyroidism/myxoedema (self-reported) 1.98 1 0 0.0 0.00 1.0e+00 PPIP5K2
Birth weight 2.04 3 0 0.0 0.00 1.0e+00 AS3MT LRRC4 SND1
Chronic bronchitis/emphysema (mother) 2.37 1 0 0.0 0.00 1.0e+00 MLH3
High blood pressure (siblings) 2.06 1 0 0.0 0.00 1.0e+00 MYST1
Forced vital capacity (FVC), Best measure 2.78 3 2 4.4 0.00 1.0e+00 ITIH4-AS1 MAPT MYST1
Body fat percentage 3.08 5 3 6.7 0.01 9.9e-01 AREL1 MYST1 NDST3 SNX19 ZDHHC5
Leg fat percentage (right) 3.06 6 3 6.7 -0.27 6.0e-01 AF131215.2 AREL1 CADM2 MYST1 NDST3 SNX19
Arm fat-free mass (right) 2.85 5 5 11.1 -0.86 6.1e-02 AF131215.2 AS3MT CADM2 MYST1 YPEL3
Comparative body size at age 10 3.19 4 3 6.7 -0.37 6.3e-01 AF131215.2 CADM2 CYB561D2 MYST1
Worry too long after embarrassment 6.69 5 3 6.7 0.98 4.4e-03 AF131215.2 KCTD10 MAPT STAG1 ZDHHC5
Number of children fathered 2.57 1 1 2.2 0.00 1.0e+00 CADM2
Age at first live birth 2.22 2 0 0.0 0.00 1.0e+00 AF131215.2 AP001877.1
Qualifications: College or University degree 3.38 6 3 6.7 -0.54 2.7e-01 AP001877.1 CADM2 MAPT PPIP5K2 SND1 ZDHHC5
Medication for pain relief, constipation, heartburn 3.45 3 1 2.2 0.00 1.0e+00 AREL1 MAPT NDST3
Whole body fat mass 3.07 6 5 11.1 -0.91 1.3e-02 AF131215.2 AS3MT CADM2 MYST1 SNX19 YPEL3
Leg fat mass (right) 3.35 6 6 13.3 -0.94 5.9e-03 AF131215.2 AS3MT CADM2 MYST1 SNX19 YPEL3
Arm predicted mass (right) 2.87 5 5 11.1 -0.86 6.0e-02 AF131215.2 AS3MT CADM2 MYST1 YPEL3
Pulse rate, automated reading 2.00 2 0 0.0 0.00 1.0e+00 CYB561D2 ZDHHC5
Alcohol intake frequency. 4.14 6 3 6.7 0.58 2.3e-01 CADM2 LRRC4 MAPT TCF4 YPEL3 ZDHHC5
Comparative height size at age 10 1.89 5 5 11.1 0.55 3.3e-01 ITIH4-AS1 MAPT STAG1 TCF4 YPEL3
Number of full sisters 2.36 1 1 2.2 0.00 1.0e+00 CADM2
Suffer from 'nerves' 7.63 6 2 4.4 0.99 5.6e-05 AF131215.2 AREL1 AS3MT CADM2 MAPT MYST1
Overall health rating 2.86 1 0 0.0 0.00 1.0e+00 MYST1
Age at last live birth 2.61 2 0 0.0 0.00 1.0e+00 AF131215.2 AP001877.1
Hypertension (Self-reported) 2.49 3 1 2.2 0.00 1.0e+00 AF131215.2 MAPT MYST1
Smoking status: Previous 3.91 1 1 2.2 0.00 1.0e+00 CADM2
Whole body fat-free mass 2.76 5 4 8.9 -0.84 7.3e-02 AF131215.2 AS3MT CADM2 MYST1 YPEL3
Leg fat-free mass (right) 2.92 5 4 8.9 -0.88 5.0e-02 AF131215.2 AS3MT CADM2 MYST1 YPEL3
Arm fat percentage (left) 3.05 6 3 6.7 -0.68 1.3e-01 AF131215.2 AS3MT MYST1 SNX19 YPEL3 ZDHHC5
Average weekly red wine intake 2.98 2 0 0.0 0.00 1.0e+00 AP001877.1 ZDHHC5
Handedness (chirality/laterality): Left-handed 3.03 2 1 2.2 0.00 1.0e+00 LRRC4 MAPT
Mood swings 7.97 5 4 8.9 0.91 3.0e-02 AF131215.2 AREL1 MAPT SLC25A17 TCF4
Loneliness, isolation 3.06 1 0 0.0 0.00 1.0e+00 MAPT
Friendships satisfaction 2.43 1 0 0.0 0.00 1.0e+00 AP001877.1
Qualifications: nursing, teaching 2.19 1 0 0.0 0.00 1.0e+00 CADM2
Mouth/teeth dental problems: Mouth ulcers 3.67 2 1 2.2 0.00 1.0e+00 AP001877.1 MAPT
Medication for cholesterol 2.75 2 0 0.0 0.00 1.0e+00 MAPT MYST1
Smoking status: Current 2.67 1 0 0.0 0.00 1.0e+00 AS3MT
Forced expiratory volume in 1-second (FEV1), predicted percentage 3.56 3 2 4.4 0.00 1.0e+00 AF131215.2 MAPT MYST1
Whole body water mass 2.76 5 4 8.9 -0.84 7.2e-02 AF131215.2 AS3MT CADM2 MYST1 YPEL3
Leg predicted mass (right) 2.92 5 4 8.9 -0.88 5.2e-02 AF131215.2 AS3MT CADM2 MYST1 YPEL3
Arm fat mass (left) 3.29 6 6 13.3 -0.93 7.3e-03 AF131215.2 AS3MT CADM2 MYST1 SNX19 YPEL3
Number of self-reported non-cancer illnesses 2.15 1 0 0.0 0.00 1.0e+00 AREL1
Average weekly champagne plus white wine intake 1.64 1 0 0.0 0.00 1.0e+00 MAPT
Miserableness 5.37 5 3 6.7 0.64 2.5e-01 AF131215.2 MAPT NDST3 STAG1 TCF4
Guilty feelings 6.29 4 3 6.7 0.98 1.7e-02 AF131215.2 AREL1 MAPT ZDHHC5
Wears glasses or contact lenses 1.69 1 0 0.0 0.00 1.0e+00 CADM2
Medication: Blood pressure 2.90 2 2 4.4 0.00 1.0e+00 AF131215.2 MAPT
High cholesterol (Self-reported) 1.97 1 0 0.0 0.00 1.0e+00 MYST1
Medication: Bendroflumethiazide 2.47 1 0 0.0 0.00 1.0e+00 AF131215.2
Medication: Paracetamol 3.87 1 1 2.2 0.00 1.0e+00 MAPT
Alcohol drinker status: Never 1.84 1 0 0.0 0.00 1.0e+00 CADM2
Ever smoked 3.68 2 1 2.2 0.00 1.0e+00 AS3MT CADM2
Basal metabolic rate 2.83 5 5 11.1 -0.85 6.6e-02 AF131215.2 AS3MT CADM2 MYST1 YPEL3
Leg fat percentage (left) 3.01 7 2 4.4 -0.29 5.2e-01 AF131215.2 AREL1 CADM2 ITIH4-AS1 MYST1 NDST3 SNX19
Arm fat-free mass (left) 2.92 5 5 11.1 -0.86 6.4e-02 AF131215.2 AS3MT CADM2 MYST1 YPEL3
Irritability 6.02 6 3 6.7 0.98 5.6e-04 AF131215.2 AREL1 MAPT MYST1 SLC25A17 TCF4
Risk taking 5.73 4 1 2.2 -0.91 8.8e-02 AF131215.2 CADM2 LRRC4 SND1
Fractured/broken bones in last 5 years 2.38 1 0 0.0 0.00 1.0e+00 SEMA3B-AS1
Diastolic blood pressure, automated reading 1.94 2 1 2.2 0.00 1.0e+00 AF131215.2 MYST1
Ever depressed for a whole week 2.53 1 0 0.0 0.00 1.0e+00 MAPT
Vascular/heart problems diagnosed by doctor 2.35 2 1 2.2 0.00 1.0e+00 AF131215.2 MYST1
Pain experienced in last month 2.92 2 0 0.0 0.00 1.0e+00 KCTD10 MAPT
Impedance of whole body 4.98 11 8 17.8 0.70 1.6e-02 AF131215.2 AREL1 AS3MT CADM2 CYB561D2 ITIH4-AS1 LRRC4 MAPT MLH3 SEMA3B-AS1 YPEL3
Leg fat mass (left) 3.30 6 6 13.3 -0.93 6.4e-03 AF131215.2 AS3MT CADM2 MYST1 SNX19 YPEL3
Arm predicted mass (left) 2.95 5 5 11.1 -0.87 5.7e-02 AF131215.2 AS3MT CADM2 MYST1 YPEL3

Associations by panel

study tissue # hits % hits/tests avg chisq
GTEx Adipose Subcutaneous 20 0.57 1.9
GTEx Adipose Visceral Omentum 11 0.54 2.0
GTEx Adrenal Gland 10 0.69 2.1
GTEx Artery Aorta 19 0.64 2.0
GTEx Artery Coronary 10 0.85 2.1
GTEx Artery Tibial 14 0.37 1.9
GTEx Brain Caudate basal ganglia 7 0.76 2.0
GTEx Brain Cerebellar Hemisphere 9 0.60 2.0
GTEx Brain Cerebellum 11 0.55 1.9
GTEx Brain Cortex 8 0.77 2.2
GTEx Brain Frontal Cortex BA9 7 0.76 2.2
GTEx Brain Hippocampus 5 0.95 2.1
GTEx Brain Hypothalamus 5 0.85 2.1
GTEx Brain Nucleus accumbens basal ganglia 7 0.81 2.0
GTEx Brain Putamen basal ganglia 6 0.96 2.1
GTEx Breast Mammary Tissue 14 0.71 2.0
GTEx Breast Mammary Tissue (Male) 10 0.84 2.0
GTEx Breast Mammary Tissue (Female) 9 0.55 1.9
GTEx Cells EBV-transformed lymphocytes 15 1.05 2.1
GTEx Cells Transformed fibroblasts 14 0.33 1.8
GTEx Colon Sigmoid 13 0.89 2.1
GTEx Colon Transverse 15 0.73 2.1
GTEx Esophagus Gastroesophageal Junction 10 0.69 2.1
GTEx Esophagus Mucosa 16 0.48 1.9
GTEx Esophagus Muscularis 15 0.46 2.0
GTEx Heart Atrial Appendage 11 0.70 2.0
GTEx Heart Left Ventricle 11 0.72 2.1
GTEx Liver 7 0.98 2.1
GTEx Lung 20 0.70 1.9
GTEx Muscle Skeletal 14 0.48 1.9
GTEx Nerve Tibial 17 0.39 1.9
GTEx Ovary 7 0.77 2.1
GTEx Pancreas 12 0.74 2.1
GTEx Pituitary 7 0.63 2.1
GTEx Prostate 8 0.96 2.1
GTEx Skin Not Sun Exposed Suprapubic 14 0.57 2.0
GTEx Skin Sun Exposed Lower leg 19 0.52 1.9
GTEx Small Intestine Terminal Ileum 7 1.52 2.3
GTEx Spleen 9 0.64 2.0
GTEx Stomach 9 0.62 2.1
GTEx Testis 22 0.70 1.9
GTEx Thyroid 21 0.53 1.9
GTEx Uterus 8 1.41 2.2
GTEx Vagina 6 0.94 2.1
GTEx Whole Blood 11 0.55 1.8
METSIM Adipose 7 0.15 1.7
NTR Blood 5 0.21 1.8
ROSMAP Brain Pre-frontal Cortex 27 0.61 2.1
YFS Blood 7 0.15 1.6
CommonMind Brain Pre-frontal Cortex 17 0.32 1.9
The Cancer Genome Atlas Bladder Urothelial Carcinoma 7 0.42 1.9
The Cancer Genome Atlas Breast Invasive Carcinoma 14 0.32 1.8
The Cancer Genome Atlas Cervical Squamous Cell Carcinoma 3 0.27 1.8
The Cancer Genome Atlas Colon Adenocarcinoma 6 0.29 1.8
The Cancer Genome Atlas Esophageal Carcinoma 5 0.73 2.0
The Cancer Genome Atlas Glioblastoma Multiforme 4 0.39 2.0
The Cancer Genome Atlas Head and Neck Squamous Cell Carcinoma 10 0.37 1.9
The Cancer Genome Atlas Kidney Renal Clear Cell Carcinoma 13 0.32 1.8
The Cancer Genome Atlas Kidney Renal Papillary Cell Carcinoma 4 0.20 1.9
The Cancer Genome Atlas Brain Lower Grade Glioma 12 0.28 1.7
The Cancer Genome Atlas Liver Hepatocellular Carcinoma 2 0.18 1.8
The Cancer Genome Atlas Lung Adenocarcinoma 12 0.41 1.9
The Cancer Genome Atlas Lung Squamous Cell Carcinoma 10 0.40 1.8
The Cancer Genome Atlas Ovarian Serous Cystadenocarcinoma 6 0.38 1.9
The Cancer Genome Atlas Pancreatic Adenocarcinoma 6 0.36 1.9
The Cancer Genome Atlas Pheochromocytoma and Paraganglioma 8 0.60 1.9
The Cancer Genome Atlas Prostate Adenocarcinoma 10 0.22 1.7
The Cancer Genome Atlas Rectum Adenocarcinoma 3 0.43 2.0
The Cancer Genome Atlas Soft Tissue Sarcoma 5 0.47 1.8
The Cancer Genome Atlas Skin Cutaneous Melanoma 1 0.19 1.7
The Cancer Genome Atlas Stomach Adenocarcinoma 5 0.30 1.8
The Cancer Genome Atlas Testicular Germ Cell Tumors 2 0.16 1.9
The Cancer Genome Atlas Thyroid Carcinoma 12 0.23 1.7
The Cancer Genome Atlas Uterine Corpus Endometrial Carcinoma 1 0.20 1.7